Dashboard

My Studies
18 Pending
My Studies
9 Approved
Next Validation Date
12th July 2022
Next P&R Review
30th April 2022
PRC Calendar
PRC Meeting Schedule
Frequency: 4th Wednesday of every month
Time: 12:00–13:00
Date US Eastern (ET) London (UK) Tokyo (JST)
Nov 26, 2025 07:00–08:00 12:00–13:00 21:00–22:00
Dec 24, 2025 07:00–08:00 12:00–13:00 21:00–22:00
Jan 28, 2026 07:00–08:00 12:00–13:00 21:00–22:00
Feb 25, 2026 07:00–08:00 12:00–13:00 21:00–22:00
Mar 25, 2026 08:00–09:00 13:00–14:00 22:00–23:00
Proposal Submission Timeline
Study Lead Entry Deadline: By the 4th Wednesday of every month (i.e. two weeks before the PRC meeting)
Presentation Materials: Proposed presentation slides must be submitted via the PRC Platform at the time of entry. (The final version of thr presentation slides acan be replaced/updated later on thre PRC Platform up to one day before the meeting.)
Studies Active This Month
Current Studies
My Approvals Needed
Date Created Study Title Study By Deadline
16/02/2022 Lorem ipsum dolor sit pmet Study Personname 09/03/2022
16/02/2022 Vis erat denique in, dicunt prodesse Study Personname 14/03/2022
16/02/2022 Vis erat denique in, dicunt prodesse Study Personname 14/03/2022
My Studies Needing Approval
Date Created Study Title Action With Deadline
16/02/2022 Sit meis deleniti eu, pri vidit meliore docendi ut Action Personname 09/03/2022
02/03/2022 An eum erat animal commodo Action Personname
Another Personname		 10/03/2022
31/12/2022 Sed pulvinar, massa vitae interdum pulvinar Action Personname 05/04/2022
31/12/2022 Sed pulvinar, massa vitae interdum pulvinar Action Personname 05/04/2022
Market Access News
Date Title Author
23/12/2022 LAST WEEK IN REVIEW Dhriti.Gupta@Eversana.com
22/12/2022 ICER Publishes Draft Evidence Report Evaluating Emerging Therapies for Alzheimer’s Disease raechel.pusateri@eversana.com
22/12/2022 In Formal Request, Alzheimer’s Association Asks CMS to Reconsider Aduhelm Coverage Decision raechel.pusateri@eversana.com
22/12/2022 NPPA Finalizes Framework for Suo Moto Corrections in Notified Prices to Improve Pricing Process Dhriti.Gupta@Eversana.com
22/12/2022 New Zealand to Source Alternative Diabetes Treatment in Response to Global Trulicity Shortage raechel.pusateri@eversana.com
22/12/2022 Happy Holidays & Warm Wishes for a Healthy New Year! anna.smith@eversana.com
22/12/2022 India's NPPA Fixes Ceiling Price of 12 Formulations Under DPCO, 2013 Dhriti.Gupta@Eversana.com
22/12/2022 Brazilian Health System and Novartis Agree to Innovative Payment Model to Cover Cost of Zolgensma raechel.pusateri@eversana.com
22/12/2022 FDA Oks Lupin to Market Generic Version of Briviact Dhriti.Gupta@Eversana.com
22/12/2022 EU Backs 2 AZ Oncology Drugs anna.smith@eversana.com
22/12/2022 ICER Issues Final Report Assessing Clinical Effectiveness and Value of Gene Therapies Targeting Hemophilia raechel.pusateri@eversana.com
22/12/2022 EUnetHTA 21 Publishes 5 More Deliverables anna.smith@eversana.com
22/12/2022 FDA Approves Roche’s Actemra for Hospitalized COVID-19 Patients anna.smith@eversana.com
22/12/2022 EC Grants ODD to Henlius’ Hansizhuang anna.smith@eversana.com
22/12/2022 Generic Association Celebrates Lauterbach for “Finally” Tackling Supply Issues anna.smith@eversana.com
22/12/2022 Over 4 Crores Health Cards Digitized in India Under ABDM Dhriti.Gupta@Eversana.com
21/12/2022 India's NPPA Revises Ceiling Price of 107 Formulations Under DPCO, 2013 Dhriti.Gupta@Eversana.com
21/12/2022 India's NPPA Fixes Ceiling Price of 10 Formulations Under DPCO, 2013 Dhriti.Gupta@Eversana.com
21/12/2022 Final “Yes” from Chamber Paves Way for AIFA Reform anna.smith@eversana.com
21/12/2022 ICER Issues Revised Evidence Report Evaluating Multiple Sclerosis Treatments raechel.pusateri@eversana.com
21/12/2022 U.S. Spending Package Addresses Accelerated Approval, Other Health Care Reforms raechel.pusateri@eversana.com
21/12/2022 Kite Pharma Announces Acquisition of Tmunity Therapeutics raechel.pusateri@eversana.com
21/12/2022 EU Approves Zynlonta for R/R DLBCL anna.smith@eversana.com
21/12/2022 Glenmark Launches Novel Triple FDC Teneligliptin with Pioglitazone & Metformin in India Dhriti.Gupta@Eversana.com
21/12/2022 ICER Updates Health-Benefit Price Benchmark for Paxlovid raechel.pusateri@eversana.com
21/12/2022 CSL Behring Selects Orsini Specialty as Hemgenix Distribution Partner raechel.pusateri@eversana.com
21/12/2022 UK MHRA Accepts EQRX’s MAA for Sugemalimab & Chemo Combo to Treat Metastatic NSCLC Dhriti.Gupta@Eversana.com
21/12/2022 After Delays, Ontario to Establish Biosimilar Switching Policy raechel.pusateri@eversana.com
21/12/2022 Japan OKs Breyanzi as 2nd-line R/R Large B-cell Lymphoma Treatment anna.smith@eversana.com
21/12/2022 Egypt to Produce 76 Cancer Drugs Locally in the First Half of 2023 Dhriti.Gupta@Eversana.com
21/12/2022 German Health Minister Announces More Major Changes to System anna.smith@eversana.com
20/12/2022 FDA Approves New Indication for Eagle Pharmaceuticals’ Pemfexy raechel.pusateri@eversana.com
20/12/2022 France Backs Orphan Drug Xenpozyme anna.smith@eversana.com
20/12/2022 Insulin Shortage in Pakistan, Experts Claim of Price Hike Up to 53% Dhriti.Gupta@Eversana.com
20/12/2022 Brazilian Pilot Project Successfully Streamlines Post-registration Requests for Biologics rachel.yalisove@eversana.com
20/12/2022 Catalyst Pharmaceuticals to Purchase U.S. Commercial Rights to Eisai’s Fycompa CIII raechel.pusateri@eversana.com
20/12/2022 Atara’s Ebvallo Receives EC Approval as First EBV+ PTLD Treatment Dhriti.Gupta@Eversana.com
20/12/2022 France Maintains Reimbursement of Remicade for Pediatric Crohn’s anna.smith@eversana.com
20/12/2022 New Zealand Funds Janssen’s Stelara and Remicade rachel.yalisove@eversana.com
20/12/2022 NICE Places Enhertu in CDF for More Advanced Breast Cancer Patients anna.smith@eversana.com
20/12/2022 Ono Collaborat%s with PrecisionLife to Discover Novel Therapies for CNS Diseases Dhriti.Gupta@Eversana.com
20/12/2022 Eisai, Washington University Collaborate to Create Novel Treatments for Neurodegenerative Disorders Dhriti.Gupta@Eversana.com
20/12/2022 Chuikyo Greenlights FY2023 Off-year Price Revision Rules, Pharma Reacts anna.smith@eversana.com
20/12/2022 Australia Updates Medicines Policy For First Time in More Than 20 Years rachel.yalisove@eversana.com
20/12/2022 EU Approves Enhertu for 2nd Line Treatment of HER2+ Gastric or GEJ Cancer Dhriti.Gupta@Eversana.com
20/12/2022 Daiichi Sankyo Launches Ezharmia in Japan for T-Cell Leukemia-Lymphoma anna.smith@eversana.com
19/12/2022 Sosei Inks Licensing Deal with Lilly in Diabetes & Metabolic Disease anna.smith@eversana.com
19/12/2022 Indian Council of Medical Research to Conduct Research in ‘Therapeutics for Inherited Rare Diseases’ Dhriti.Gupta@Eversana.com
19/12/2022 Korea Reveals ICER Evaluations for First Time in 15 Years rachel.yalisove@eversana.com
19/12/2022 IMC Supports Delay in PMPRB Guideline Implementation rachel.yalisove@eversana.com
19/12/2022 FDA Approves Ferring Pharma’s Gene Therapy for Bladder Cancer raechel.pusateri@eversana.com
19/12/2022 Vraylar Receives FDA Nod for Treatment of Major Depressive Disorder raechel.pusateri@eversana.com
19/12/2022 TLV Includes Farydak in High-cost Protection for Certain MM Patients Luke.Hannaford@Eversana.com
19/12/2022 Sanofi Expands Collaboration With Innate for Natural Killer Cell Therapeutics in Oncology Luke.Hannaford@Eversana.com
19/12/2022 LAST WEEK IN REVIEW Dhriti.Gupta@Eversana.com
19/12/2022 G-BA Gives Orphan Drug Brineura Highest Rating in Latest Meeting anna.smith@eversana.com
19/12/2022 Europe Launches Cross-border Project to Improve Affordability & Accessibility of Innovation anna.smith@eversana.com
19/12/2022 COVID-19 Vaccines Saved Australia’s Economy, Finds New Study rachel.yalisove@eversana.com
19/12/2022 FDA Lifts Partial Clinical Hold for Pediatric Patients in Bluebird Bio Sickle Cell Disease Studies raechel.pusateri@eversana.com
19/12/2022 Shilpa Medicare Launches Capebel 1000mg Dispersible Tablets to Treat Metastatic Breast Cancer in India Dhriti.Gupta@Eversana.com
19/12/2022 Oxford’s Ebola Vaccine Manufactured by Serum Institute India Shipped to Uganda Dhriti.Gupta@Eversana.com
19/12/2022 U.S. Congress Revisits Antimicrobial Netflix Model rachel.yalisove@eversana.com
19/12/2022 Madrigal’s NASH Candidate Achieves Promising Phase 3 Results rachel.yalisove@eversana.com
19/12/2022 France in Favor of Reimbursing Kymriah for Certain Follicular Lymphoma Patients Luke.Hannaford@Eversana.com
19/12/2022 France Backs Keytruda as Adjuvant Treatment for Stage IIB, IIC, or III Melanoma Following Complete Resection Luke.Hannaford@Eversana.com
19/12/2022 Janssen Withdraws EU Application Seeking Approval of Imbruvica for Patients With Untreated MCL Luke.Hannaford@Eversana.com
19/12/2022 Lotus Pharmaceuticals Acquires Eli Lilly’s Cancer Drug Alimta in Taiwan Dhriti.Gupta@Eversana.com
19/12/2022 Prescryptive Health and Eli Lilly to Offer Value-Based Payment Model for Insulin raechel.pusateri@eversana.com
19/12/2022 Attralus Announces Orphan Drug Designation for AT-01 in Europe raechel.pusateri@eversana.com
19/12/2022 FDA Greenlights Glenmark’s Generic Equivalent of Cardene Hypertension Drug Dhriti.Gupta@Eversana.com
19/12/2022 Reata & Lilly Withdraw Drugs from EMA anna.smith@eversana.com
16/12/2022 European Commission Lays Out Further Info on EU Pharmaceutical Strategy anna.smith@eversana.com
16/12/2022 AbbVie Leaves PhRMA & Other Industry Groups rachel.yalisove@eversana.com
16/12/2022 Fimea Publishes Assessment of Vyvgart for Myasthenia Gravis Luke.Hannaford@Eversana.com
16/12/2022 48% Of Listed Products in Japan to Face Price Cuts Under Off-year Revision anna.smith@eversana.com
16/12/2022 ABPI Warns 'Skyrocketing' VPAS Clawback Puts UK Sector at Risk Luke.Hannaford@Eversana.com
16/12/2022 Pakistan’s Health Ministry Seeks Investigation into Non-Opening of LCs Dhriti.Gupta@Eversana.com
16/12/2022 Spanish Association Calls for Direct Collaboration with Health Administrations to Improve Financing of Drugs Luke.Hannaford@Eversana.com
16/12/2022 Fimea Publishes Economic Assessment of Kapruvia for Severe Pruritus Luke.Hannaford@Eversana.com
16/12/2022 CHMP Recommends 5 New Drugs Luke.Hannaford@Eversana.com
16/12/2022 FDA Grants Orphan Drug Designation to Ocugen’s Investigational Rare Retinal Disease Drug raechel.pusateri@eversana.com
16/12/2022 Torrent Pharma Ties Up with BI India to Co-market its Anti-diabetic Drug Dhriti.Gupta@Eversana.com
16/12/2022 Federal Judge Upholds Arkansas State Law Protecting the Use of Contract Pharmacies under 340B raechel.pusateri@eversana.com
16/12/2022 Nexium, Lexapro, Bonviva Face Generic Entry in Japan anna.smith@eversana.com
16/12/2022 France Grants Early Access to Amvuttra for hATTR Amyloidosis Luke.Hannaford@Eversana.com
16/12/2022 New York’s Community Care Health Orgs Brace for Loss in Federal Reimbursement Funding rachel.yalisove@eversana.com
15/12/2022 NHS Director Hails Commercial Deals & VPAS, Despite Industry Concern anna.smith@eversana.com
15/12/2022 TLV Forecasts SEK 2.4B in Savings From Side Agreements in 2022 Luke.Hannaford@Eversana.com
15/12/2022 Takeda Launches Cinryze in India to Treat Rare Genetic Condition Hereditary Angioedema Dhriti.Gupta@Eversana.com
15/12/2022 JB Pharma Inks Deal with Glenmark to Acquire Razel Franchise for India & Nepal Dhriti.Gupta@Eversana.com
15/12/2022 Amid Nationwide Shortage, Alberta, Canada Secures Imported Pain Meds from Turkey rachel.yalisove@eversana.com
15/12/2022 Wales Recommends Votubia for Tuberous Sclerosis Complex Luke.Hannaford@Eversana.com
15/12/2022 EU Backs Sanofi’s Dupixent for Prurigo Nodularis anna.smith@eversana.com
15/12/2022 AEMPS Issues Recommendations to Alleviate Supply Problems with Fibrinolytic Drugs Luke.Hannaford@Eversana.com
15/12/2022 State Prisons Gain Purchase Power for Gilead’s Hep C Drugs rachel.yalisove@eversana.com
15/12/2022 Innovent Biologics and LG Chem Enter License Agreement Regarding Tigulixostat raechel.pusateri@eversana.com
15/12/2022 Angelini Pharma Launches Ontozry in France for Epilepsy Luke.Hannaford@Eversana.com
15/12/2022 50% of EMIG Companies to Reduce Supply to UK in 2022 anna.smith@eversana.com
15/12/2022 FDA Approves Fresenius Biosimilar Referencing Humira raechel.pusateri@eversana.com
15/12/2022 FDA Grants Orphan Drug Designation to PharmaTher’s Ketamine raechel.pusateri@eversana.com
Notifications

This is the task, but I'm not sure how long this is?

By Person Name :: Due DD/MM/YY

This is the task, but I'm not sure how long this is? It could potentially be quite long I guess so lets just see what that looks like.

By Person Name :: Due DD/MM/YY

This is the task, but I'm not sure how long this is?

By Person Name :: Due DD/MM/YY

This is the task, but I'm not sure how long this is?

By Person Name :: Due DD/MM/YY

P&R Questionnaire

??? – Reference Basket of user’s country, and also P&R Forms waiting for validation (although this latter might also / exclusively be in a “Tasks” widget

Country Approval Flow

??? – Steps of the approval flow for their country, including names of approvers at each stage

Report or Chart

??? – mini version of system reports & charts, or custom built – clicking would load full version

Quick Access Reports

??? – a list of reports that the user (or Admin) has chosen to appear on homepage

ID Name Desc
001 Name 1 Info here
002 Name 2 What I need to know
Task Lists
  • Rejected
    Task Number 1

    Last Updated DD/MM/YY

  • Task Number 2

    Last Updated DD/MM/YY

  • Task Number 3

    Last Updated DD/MM/YY

  • Task Number 4

    Last Updated DD/MM/YY

  • Task Number 5

    Last Updated DD/MM/YY

  • Task Number 6

    Last Updated DD/MM/YY

  • Task Number 7

    Last Updated DD/MM/YY

  • Task Number 8

    Last Updated DD/MM/YY

IRP Calendar

??? – Date items from the IRP calendar, filtered by Affiliate(s). 3 months behind, 9 months ahead

Validate Prices

??? – Studies due to go live in next two weeks but not yet validated. Also would show when price validation was last done and when due

Support Contacts

Need help with the RWE system? Contact one of the following:

Contact Email
Firstname Lastname
Role Name		 firstname.lastname@domain.com
Firstname2 Lastname2
Role Name		 firstname2.lastname2@domain.com
System Messages2
This is a system message of some kind.

Suspendisse venenatis sollicitudin erat in gravida. Sed eget nisl tristique, commodo lectus sit amet, vulputate sem. Cras porttitor lorem ipsum, sit amet iaculis massa feugiat vitae.

This is another system message.

Sed eget nisl tristique, commodo lectus sit amet, vulputate sem. Cras porttitor lorem ipsum, sit amet iaculis massa feugiat vitae.

Some button